After J.P. Morgan and Piper Jaffray gave Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Yaron Werber maintained a Buy rating on Ultragenyx Pharmaceutical, Inc. yesterday and set a price target of $79. The company’s shares closed yesterday at $67.25.
According to TipRanks.com, Werber is a 5-star analyst with an average return of 14.9% and a 66.3% success rate. Werber covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Unum Therapeutics Inc, and Acceleron Pharma.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ultragenyx Pharmaceutical, Inc. with a $74.67 average price target, representing an 11.0% upside. In a report released yesterday, Piper Jaffray also maintained a Buy rating on the stock with a $75 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $90.98 and a one-year low of $37.44. Currently, Ultragenyx Pharmaceutical, Inc. has an average volume of 632.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita.
